KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Accured Expenses (2024 - 2025)

Historic Change in Accured Expenses for AbCellera Biologics (ABCL) over the last 2 years, with Q3 2025 value amounting to $5.1 million.

  • AbCellera Biologics' Change in Accured Expenses rose 2222.76% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year change of. This contributed to the annual value of $10.6 million for FY2024, which is 17041.18% up from last year.
  • AbCellera Biologics' Change in Accured Expenses amounted to $5.1 million in Q3 2025, which was up 2222.76% from -$3.9 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Change in Accured Expenses ranged from a high of $6.6 million in Q4 2024 and a low of -$4.9 million during Q1 2024